Text of MN SF 1178 (2017)
Gender dysphoria treatment medical assistance (MA) coverage requirement when medically necessary
Legislative text is a public record. Where LegiScan supplied it, the CC BY 4.0 credit applies.
Source: LegiScan. Bill data and text from LegiScan (legiscan.com), licensed CC BY 4.0 and used in modified form. LegiScan does not endorse the Trans Data Initiative. License: CC BY 4.0(opens another site). Source page(opens another site)
As introduced
1,926 characters
1.1
A bill for an act
1.2
relating to human services; requiring medical assistance to cover medically
1.3
necessary gender dysphoria and certain prescribed drugs for treatment of gender
1.4
dysphoria; amending Minnesota Statutes 2016, section 256B.0625, subdivision
1.5
3a, by adding a subdivision.
1.6
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
1.7
Section 1. Minnesota Statutes 2016, section 256B.0625, subdivision 3a, is amended to
1.8
read:
1.9
Subd. 3a. Sex reassignment surgery Treatment of gender dysphoria. Sex reassignment
1.10
surgery is not covered, unless medically necessary.
1.11
Sec. 2. Minnesota Statutes 2016, section 256B.0625, is amended by adding a subdivision
1.12
to read:
1.13
Subd. 13k. Treatment of gender dysphoria. Notwithstanding subdivision 13d, paragraph
1.14
(b), clause (1), the commissioner may include drugs for the treatment of gender dysphoria
1.15
within the drug formulary established under subdivision 13d if:
1.16
(1) the drug is approved for marketing by the United States Food and Drug
1.17
Administration;
1.18
(2) the dose and indication for use of the drug is recommended by a clinical guideline
1.19
or practice parameter included in the National Guideline Clearinghouse maintained by the
1.20
United States Department of Health and Human Services Agency for Healthcare Research
1.21
and Quality; and
1
Sec. 2.
17-2573
as introduced
02/01/17
REVISOR
ACF/LP
SENATE
STATE OF MINNESOTA
S.F. No. 1178
NINETIETH SESSION
(SENATE AUTHORS: DIBBLE and Simonson)
OFFICIAL STATUS
D-PG
DATE
Introduction and first reading
02/20/2017
Referred to Health and Human Services Finance and Policy
2.1
(3) there is not another drug or regimen available within the formulary to treat the
2.2
condition.
2
Sec. 2.
17-2573
as introduced
02/01/17
REVISOR
ACF/LP